Is the Fisher & Paykel Healthcare Corp Ltd share price a BARGAIN?

Credit: Anoto AB

The Fisher & Paykel Healthcare Corp Ltd (ASX: FPH) share price headed marginally higher following the announcement of a bumper profit result this morning.

Reporting in New Zealand dollars, during the six-month period ended 30 September 2015, the $4.5 billion company announced a 20% increase in revenue, to $381 million, and a profit of $62 million, up 27% on the prior corresponding period.

Fuelling profit growth was a 2.76% widening of the group’s gross profit margin, which came in at an enviable 63.3%, thanks to a favourable product mix, and increased production and efficiency gains at its operations in Mexico.

“The record result is attributable to a continuation of our consistent growth strategy, which has driven strong revenue growth in both of our major product groups and further gross margin improvements,” CEO Michael Daniell said.

During the half, Fisher & Paykel moved to a direct-to-consumer sales model for their respiratory and acute care/hospital product group. “With the move to a direct sales model in the US, as we have already done in our other major markets, we expect that the increased sales focus will enable us to maximise opportunities and increase revenue growth in the US,” Mr Daniell added.

The Auckland-based company said 83% of sales were derived from recurring items such as consumables and accessories. Sales of masks used for the treatment of Obstructive Sleep Apnoea (OSA) rose 25% in constant currency.

Investment in research & development rose 14.3% to $35.8 million, or 9.4% of operating revenue. “We have a significant pipeline of new products that we expect to release in the coming year including new humidifier controllers, flow generators, masks and consumables,” Fisher & Paykel’s Senior Vice President of Products and Technology and CEO Designate, Lewis Gradon, said.

Pleasingly, the company announced an interim dividend of 6.7 cents per share, up 16% from last year.

Looking towards 2017, Mr Daniell said, “Our strategic direction remains consistent as we continue to develop new, innovative products, expand our market opportunities and grow our international presence.”

While currency exchange rates have been slightly less favourable than when the group previously set profit guidance, Mr Daniell said, “we continue to expect full year operating revenue to be approximately 800 million NZ dollars and net profit after tax to be approximately 135 to 140 million NZ dollars.”

Are Fisher & Paykel shares a buy?

Fisher & Paykel competes with both RedMed Inc. (CHESS) (ASX: RMD) and Philips Respironics in the huge market for the treatment of sleep apnoea. The company believes there are 100 million patients who could benefit from its products worldwide, but with changing demographics it forecasts that number to double in the next 10 to 15 years.

Unfortunately, after rising some 23% in 2015, the Fisher & Paykel share price now appears roughly in line with fair value. However, if you’re investing for the ultra-long-term (10 years or more), I think it’s certainly worthy of a spot on your watchlist.

Get our #1 dividend stock idea

Fisher & Paykel shares may be slightly outside the buy zone, but that's okay with me because Scott Phillips, lead advisor of Motley Fool Share Advisor, has just announced his #1 dividend stock of 2015-2016 - I think it is a GREAT BUY today! Best of all, for a limited time, Scott is giving away its name and stock code free in his brand-new investment report! Simply click here, enter your email address and we'll send you his report. No Credit Card details or payment required.

Motley Fool contributor Owen Raskiewicz owns shares of ResMed Inc.

Owen welcomes your feedback on Google plus (see below), LinkedIn or you can follow him on Twitter @ASXinvest.

Unless otherwise noted, the author does not have a position in any stocks mentioned by the author in the comments below. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

Two New Stock Picks Every Month!

Not to alarm you, but you’re about to miss a very important event! Chief Investment Advisor Scott Phillips and his team at Motley Fool Share Advisor are about to reveal their latest official stock recommendation. The premium “buy alert” will be unveiled to members and you can be among the first to act on the tip.

Don’t let this opportunity pass you by – this is your chance to get in early!

Simply enter your email now to find out how you can get instant access.

By clicking this button, you agree to our Terms of Service and Privacy Policy. We will use your email address only to keep you informed about updates to our website and about other products and services we think might interest you. You can unsubscribe from Take Stock at anytime. Please refer to our Financial Services Guide (FSG) for more information.